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Cholesteatoma is an epidermoid cyst, which ismost frequently found in themiddle ear.Thematrix of cholesteatoma is histologically
similar to the matrix of the epidermoid cyst of the skin (atheroma); their epithelium is characterized by hyperproliferation. The
c-MYC protooncogene located on chromosome 8q24 encodes a transcription factor involved in the regulation of cell proliferation
and differentiation. Previous studies have found aneuploidy of chromosome 8, copy number variation of c-MYC gene, and the
presence of elevated level c-MYC protein in cholesteatoma. In this study we have compared the expression of c-MYC gene in
samples taken from thematrix of 26 acquired cholesteatomas (15 children and 11 adults), 15 epidermoid cysts of the skin (atheromas;
head and neck region) and 5 normal skin samples (retroauricular region) using RT-qPCR, providing the first precise measurement
of the expression of c-MYC gene in cholesteatoma. We have found significantly elevated c-MYC gene expression in cholesteatoma
compared to atheroma and to normal skin samples.Therewas no significant difference, however, in c-MYCgene expression between
cholesteatoma samples of children and adults.The significant difference in c-MYC gene expression level in cholesteatoma compared
to that of atheroma implies a more prominent hyperproliferative phenotype which may explain the clinical behavior typical of
cholesteatoma.
1. Introduction
Several types of keratinous cysts are known, such as epi-
dermal cyst of the skin (atheroma) and cholesteatoma.
Cholesteatoma is an epidermoid cyst, characterized by
hyperproliferation of multilayered keratinizing squamous
epithelium, causing bone erosion and destruction in the
middle ear. Atheroma is a benign tumor. The epithelium
wall of these cysts is called matrix; the surrounding tissue,
the perimatrix or lamina propria, is the peripheral part of
the cyst. [1–3]. Although epidermoid cyst of the skin and
cholesteatoma are histologically very similar, the clinical
behavior of cholesteatoma differs markedly from that of
atheroma [4].
Several theories can be found in the literature to explain
the development and aggressive behavior of cholesteatoma,
among them changes in the physiological and anatomic
conditions of the middle ear or molecular abnormalities [1,
2, 5–8].
According to recent studies, the cholesteatoma has an
assumed neoplastic behavior characterized by chromosomal
abnormalities [9]. Previous studies had shown aneuploidy of
chromosome 8 and as a consequence copy number variation
of c-MYC gene and the presence of elevated level c-MYC
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protein in cholesteatoma [9–12]. The c-MYC gene is a pro-
tooncogene, located on chromosome 8q24. It is well known
that deregulated expression of this gene plays a significant
role in tumorogenesis; genomic alterations affecting chromo-
some 8q24 are frequent in cancers [13, 14].
These reports, however, did not provide an exact mea-
surement of the expression of the c-MYC gene itself. The
characteristic alterations present in cholesteatoma indicate
abnormal c-MYC gene expression and could warrant for the
precise determination of the c-MYC gene expression level in
cholesteatoma samples.
Compared to the methods used in previous studies
RT-qPCR provides a more accurate measurement of gene
expression level. It enables to detect and quantify the extent
of abnormal c-MYC gene expression that could be present in
cholesteatoma.
The aim of our study was to determine the expression
level of the c-MYC protooncogene, a plausible causative
factor of the hyperproliferation of the epithelium (matrix)
in cholesteatoma. According to our knowledge, this is the
first study that uses RT-qPCR methodology to measure c-
MYC gene expression in cholesteatoma samples and the
first to compare c-MYC gene expression in an inflammatory
destructive cholesteatoma with that of the histologically
similar benign epidermoid cyst of the skin, atheroma.Normal
skin samples were used as controls in our experiments.
2. Materials and Methods
2.1. Patients and Tissue Sample Preparation. All samples were
obtained with informed patient consent and with approval
from the Research Ethics Committee of University of Debre-
cen Medical and Health Science Center that approved the
clinical protocol and the study (protocol number 3047-2009).
Our study populations consisted of 26 patients with
acquired cholesteatoma (11 females and 15 males), 15 patients
with atheroma (head-neck region), and 5 normal skin sam-
ples (retroauricular region). The eardrums were perforated
in all cholesteatoma patients, and all patients underwent
primary or secondary surgery. The age of the cholesteatoma
patients ranged between 4 and 65 years (average: 23.4 years).
Patients were divided into a pediatric (15 cases; 0–18 years)
and an adult group (11 cases; over 19 years). The clinical
samples were provided by the Children’s Hospital Heim Pa´l,
Regional Educational Hospital “Jo´sa Andra´s,” and the Uni-
versity of Debrecen Medical and Health Science Center. The
diagnosis of cholesteatoma and atheroma in all specimens
was confirmed by histopathologic examination.
All sampleswere surgically removed. Immediately follow-
ing surgery, the samples were soaked and fixed in RNAlater
RNA Stabilization Reagent (Life Technologies) and stored at
4∘C until RNA extraction.
2.2. RNA Extraction. Before RNA extraction the excess
RNAlater solution was blotted off from the samples and
the matrixes of cholesteatoma and the atheroma specimens
were carefully and manually cleaned from the surrounding
tissues. Optimally 70mg tissue sample was homogenized in
TRI Reagent with a rotor-stator tissue homogenizer and total
RNA was extracted from the specimens using the RiboP-
ure kit following the manufacturer’s instructions (Ambion
(Europe) LTD, Huntingdon, UK). The concentration and
quality of the RNA samples were assessed by a NanoDropTM
1000A spectrophotometer (Thermo Scientific, Wilmington,
USA).
2.3. cDNA Synthesis and Real-Time PCR. First-strand synthe-
sis for real-time PCR cDNA preparation was performed on
2 𝜇g of total RNA, using the High Capacity cDNA Reverse
Transcription Kit with RNase inhibitor (Applied Biosystems)
in a final volume of 20𝜇L.The sampleswere incubated at 25∘C
for 10min and 37∘C for 120min; the reverse transcriptase
was inactivated at 85∘C for 5min and cooled at 0∘C for an
additional 5min.
Determination of the target c-MYC gene mRNA expres-
sion was performed on an ABI Prism 7900HT Sequence
Detection System (Applied Biosystems) by fluorescent Taq-
Man methodology using prevalidated TaqMan Gene Expres-
sion Assays (MYC Assay ID Hs00153408 m1). Gene expres-
sion quantitation was performed according to the man-
ufacturer’s instructions; briefly a total of 20 𝜇L of PCR
mix containing TaqMan Universal PCR master mix with
AmpliTaq Gold DNA Polymerase, TaqMan Gene Expression
Assay mix, and 4 ng of cDNA was used. Amplification was
performed for 40 cycles, including denaturation at 95∘C for
15 seconds and annealing at 60∘C and extension at 72∘C for
60 and 30 seconds, respectively. Relative gene expression
levels were calculated by the comparative critical threshold
method (2−ΔΔCT) using PPIA as a housekeeping gene to
normalize expression levels. The housekeeping gene PPIA
was coamplified with c-MYC on the same plate. Results are
expressed as relative increase or decrease compared to the
normal control group.
2.4. Statistical Analysis. The nonparametric Mann-Whitney
𝑈 test was performed to assess the statistical significance
of differences between relative mRNA levels. The GraphPad
Prism software was used for the analysis and statistical
significance was defined as 𝑃 < 0.05.
3. Results
In order to compare c-MYC gene expression 26 acquired
cholesteatoma samples (15 children and 11 adults), 15
atheroma samples, and 5 normal skin samples were col-
lected. The demographic data and surgical parameters of
cholesteatoma patients are summarized in Table 1. Typically
cholesteatoma extended to the atticus and antrum; in 24 out
of the 26 patients the ossicular chain was destructed and in
2 cases it was intact. The recurrent rate of cholesteatoma was
higher in the pediatric group compared to that of the adult
group (31% and 27%, resp.).
To quantitate c-MYC gene expression, total RNA content
was extracted from the homogenized surgical samples and
first-strand cDNA was generated from equal amounts of
RNA. C-MYC target sequence was amplified and quantitated
by a TaqMan methodology based real-time PCR (RT-PCR)
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Table 1: Demography of cholesteatoma patients and surgical findings.
Sample number Age (year) Gender∗ Expansion Chain of auditory ossicles Recurrence
1 25 M Atticus + antrum Destroyed Yes
2 11 F Atticus + mastoid Destroyed No
3 32 F Atticus + antrum Destroyed No
4 42 M Atticus Destroyed No
5 58 F Atticus + antrum Destroyed No
6 14 M Atticus + mastoid Destroyed Yes
7 8 M Atticus Destroyed Yes
8 11 M Atticus, mastoid Intact Yes
9 22 F Mastoid Destroyed Yes
10 60 F Atticus Destroyed Yes
11 62 M Atticus, mastoid Destroyed No
12 12 M Atticus, mastoid Destroyed No
13 8 M Atticus, antrum Destroyed No
14 16 F Atticus, antrum Intact No
15 34 F Atticus, mastoid Destroyed Yes
16 11 M Atticus, mastoid Destroyed Yes
17 16 M Attius, mastoid Destroyed Yes
18 10 F Atticus, mastoid Destroyed Yes
19 27 F Atticus, mastoid Destroyed Yes
20 31 M Atticus, mastoid Destroyed Yes
21 8 F Atticus, mastoid Destroyed No
22 4 M Atticus, antrum Destroyed Yes
23 6 M Atticus Destroyed No
24 4 M Atticus Destroyed No
25 11 F Atticus Destroyed Yes
26 65 M Atticus, mastoid Destroyed Yes
∗F: female and M: male.
assay. Our RT-QPCR data show that the PPIA normalized c-
MYC expression was identical in the control and atheroma
samples (𝜇 ± SD = 1.17 × 10−3 ± 1.01 × 10−3) in normal skin
and 1.8 × 10−3 ± 3.2 × 10−5 in atheroma (𝑃 = 0.137). In
cholesteatoma samples, however, c-MYC expression level was
significantly elevated (𝜇 ± SD = 6.9 × 10−3 ± 1.08 × 10−3)
compared to that in atheroma (𝑃 = 0.0001) and in control
samples (𝑃 = 0.012) (Figure 1).
Cholesteatoma patients were divided into two groups: a
pediatric (age < 18) and an adult group (age > 19). Mean
relative expression level of c-MYC in cholesteatoma samples
of children was slightly higher than in the adults (𝜇 ± SD
= 9.1 × 10−3 ± 1.17 × 10−3 and 6.3 × 10−3 ± 1.0 × 10−3,
resp.); however the data showed wider distribution in the
pediatric samples. The difference in c-MYC expression was
not significant between the two cholesteatoma groups (𝑃 =
0.195). c-MYC expression was significantly higher in both
cholesteatoma groups compared to that of atheroma speci-
mens and to controls (cholesteatoma-atheroma comparison:
𝑃children = 0.001 and 𝑃adults = 0.002; cholesteatoma-control
comparison: 𝑃children = 0.0145 and 𝑃adults = 0.0312) (Figure 2).
The highest c-MYC expression was found in children with
recurrent cholesteatoma; however, the difference was not
significant in any of the pairwise comparisons (Figure 3).
4. Discussion
Several types of keratinous cysts are known, which are
characterized by different keratinisation mechanisms. The
matrix of the keratinous cyst contains mainly epithelial
cells (keratinous cells) with different differentiation states
[4]. Cholesteatoma is a multilayered keratinizing squamous
cyst; it is characterized by uncoordinated cell proliferation,
invasion of surrounding tissues, altered differentiation states,
intense inflammation, and recurrence, causing several clin-
ical complications. Atheroma is a keratinous cyst too. It is
a benign tumor; it can be manifested anywhere in the body
without serious complications [1–3]. Atheroma is delineated
by a multilayered epidermal-like epithelium including a
characteristical granular layer, and the content of the cyst
is laminated keratin. The matrixes of the cholesteatoma
and atheroma are histologically very similar; however, their
surrounding environment and behavior are different [1–4].
The cholesteatomatous suppurative otitis media is a chronic
inflammatory process and numerous studies described the
involvement of different inflammatorymediators (EGF, TGF-
alpha, beta, IL-6, IL-1, and GM-CSF), cell surface markers,
and adhesion molecules (1,6 integrin, ICAM ELAM) in the
pathomechanism of the disease. The interactions among

























Figure 1: c-MYC gene expression in control, atheroma, and
cholesteatoma samples. The housekeeping gene cyclophilin A
(PPIA) was used to normalize mRNA expression levels. The mean
value and the standard deviation of the data are shown on the figure.

























































Figure 2: The distribution of c-MYC gene expressions values in
samples of children and adult cholesteatoma patients compared
to that of atheroma and control samples. The housekeeping gene
cyclophilin A (PPIA) was used to normalize mRNA expression
levels. Mean values and standard deviations are shown on the figure.
The significance levels of the data are given in the text.
these mediators could initiate modified signal transduction
pathways in keratinocytes of cholesteatoma leading to a
higher proliferation rate and a modified cell differentiation
pathway [2, 9, 15–19]. However, the exact etiopathogenesis of
the cholesteatoma is still not known.
Several recent studies have found chromosome aberra-

































































Figure 3:The c-MYC gene expression values in samples of relapsing
and nonrelapsing cholesteatomas in children and in adult patients.
There was no significant difference in the expression of the c-MYC
gene between these groups. The housekeeping gene cyclophilin A
(PPIA) was used to normalizemRNA expression levels.Mean values
and standard deviations are shown on the figure.
the malfunction of factors involved in the regulation of cell
cycle, like tumor suppressor genes or protooncogenes [9–
12, 19]. Ozturk and coworkers showed the aneuploidy of
chromosome 8 and subsequent copy number variation of
the c-MYC gene in cholesteatoma [11]. Increased level of c-
MYC protein was also detected by immunohistochemistry in
cholesteatoma [12].
The c-MYC gene is located on chromosome 8q24; it codes
for a transcription factor that plays an important role in
cell cycle progression, in the regulation of cell proliferation,
differentiation, and apoptosis. Deregulated expression of this
gene has been associated with a variety of tumors, like
lymphomas, kidney, lung, colon tumors, and melanomas. C-
MYC protooncogene is frequently dysfunctional in head and
neck cancer cells and it might be involved in hyperprolifer-
ation of epithelial cells [13, 14]. Since abnormal expression
of c-MYC occurs in several tumors, its expression level has
prognostic importance.
The c-MYC protein is a multifunctional transcription
factor involved in the activation of DNA replication; over-
expression of this protooncogene may induce chromosome
aberrations and an overall dysfunction in the regulation of
the cell cycle [13, 14, 20, 21].
In our study we examined the c-MYC expression in the
matrix of two types of keratinous cysts.On the basis of clinical
data, the 26 acquired cholesteatomas were divided into two
groups, a pediatric and an adult group. Both groups were
subdivided into patients with relapsing and nonrelapsing
group. We have found higher recurrence rate in the pediatric
group compared to that of adults.
BioMed Research International 5
In the present study we have provided a quantitative
assessment of c-MYC gene expression for epidermal cysts
using RT-QPCR methodology. Our results showed a signif-
icantly elevated expression of c-MYC gene in cholesteatoma,
compared to that of atheroma and normal skin samples.The
expression level of c-MYC gene in pediatric cholesteatoma
was higher than in adults. The highest c-MYC expression
level was found in children with recurrent cholesteatoma.
According to our opinion the c-MYC expression level is a
prognostic factor in cholesteatoma, indicating the clinical
aggressiveness and the susceptibility of relapse.
Welkoborsky et al. examined 40 adults and 14 children
who acquired cholesteatomas. Immunohistochemical meth-
ods were used to determine the expression of prolifera-
tion and cell surface markers (MIB-1 and PCNA markers).
The cell proliferation indices were higher in both groups
compared to normal auditory canal skin samples; however,
the highest values were detected for the pediatric group
than for the adult one. On the basis of these results, the
pediatric cholesteatomas can be characterized with more
aggressive proliferative phenotype [18]. This examination
is in agreement with the increased c-MYC expression in
childhood cholesteatomas found in our study. This genetic
deviation was also supported by the clinical data of our study
population.
Several research groups have found an elevated level
of certain inflammatory mediators involved in the inflam-
mation processes in cholesteatoma [15–17]. On the basis
of patients’ data Welkoborsky et al. concluded that the
intensity of inflammation process was higher in pediatric
cholesteatoma than in adults [18].
Based on these results, one might conclude that the
increased expression of the c-MYC in cholesteatoma is
induced by inflammation. However, according to the liter-
ature, inflammation factors do not play a direct regulatory
role in the expression of the c-MYC gene. Interestingly recent
results show that increased c-MYC expression can cause
mitochondrial dysfunction leading to reactive oxygen species
production and as a consequence can fuel inflammation
[22]. According to the “field cancerization” theory described
by Slaughter and cited by Schwartz et al. tumorogenesis is
a multiple stage process [23]. Chronic inflammation can
increase cancer risk (extrinsic pathway); however, genetic
alterations (intrinsic pathway and oncogene activation) are
also required for tumorogenesis [24]. A previous case study
has reported that after the removal of cholesteatoma a
squamous epithelium carcinoma developed in themiddle ear
of the patient [25].
The elevated c-MYC level reported in this study might
have a dual role; it promotes cell proliferation and can sustain
the chronic inflammation process in cholesteatoma.
5. Conclusion
The increased c-MYC expression level in the cholesteatoma
matrix compared to that of the atheroma matrix might
explain the more aggressive behavior of cholesteatoma that
results in clinical complications and it also explains its more
intensive proliferation.The elevated c-MYC expression could
lead to increased cell proliferation rate which is associated
with frequent relapse. Our finding that c-MYC expression
was higher in the cholesteatoma matrix of children could
explain the higher recurrence rate in this group compared
to that of the adult group. Based on the elevated c-MYC
expression level, cholesteatoma is similar to a neoplastic
malformation; however, further experiments are needed to
clarify its role in the pathogenesis of cholesteatoma.
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